Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia.

Venetoclax-obinutuzumab therapy successfully induced remission of acquired von Willebrand syndrome (AVWS) in a 72-year-old patient with chronic lymphocytic leukemia (CLL). Initially diagnosed with CLL, the patient later experienced severe bleeding due to AVWS, as evidenced by reduced factor VIII (FVIII) and von Willebrand factor (VWF) levels. Despite initial treatment with VWF/FVIII concentrates and tranexamic acid, persistent bleeding prompted the initiation of venetoclax-obinutuzumab. This regimen resulted in normalization of coagulation parameters and undetectable minimal residual disease, indicating effective CLL control and subsequent AVWS remission. This case highlights the potential of targeted CLL therapies in the management of rare associated hematologic complications.